Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Clinical-stage biotech Alterity Therapeutics has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as it advances its lead drug candidate ATH434 toward a ...

Shares of Theravance Biopharma TBPH plunged 26% after the company announced the failure of the late-stage CYPRESS study ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Sarma is presented as a system capable of delivering fewer but more accurate strikes while minimizing exposure of its crew.Dmitry/Aterrassi Russia has showcased its new multiple launch rocket system ...

Stanley "Stan" Schillinger, 57, of Moro, passed away on Tuesday, February 3, 2026, at Staunton Health and Rehab, with his wife and daughter, Jessica, by his side following a battle with MSA (Multiple ...

Stanley "Stan" Schillinger, 57, of Moro, passed away on Tuesday, February 3, 2026, at Staunton Health and Rehab, with his wife and daughter, Jessica, by his side following a battle with MSA (Multiple ...

1 MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands 2 MS Center Amsterdam, Anatomy and Neurosciences, Vrije ...

A new study found paramagnetic rim lesions, indicating chronic inflammation, in nearly 75% of children with MS. More lesions, or PRLs, correlate with faster brain atrophy, suggesting aggressive ...